Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EGFR mutation analysis on circulating free DNA in NSCLC: a single-center experience.

Journal of cancer research and clinical oncology - 1 Aug 2021

Ianza Anna, Di Chicco A, Biagi C, Giudici F, Dicorato A, Guglielmi A, Variola F, Tomasi S, Roviello G, Generali D, Zanconati F

Abstract excerpt

PURPOSE: Monitoring mutation status in circulating free DNA (cfDNA) during target therapy could hold significant clinical importance in non-small cell lung cancer (NSCLC). Our aim is to establish if EGFR mutational status change on cfDNA has predictive value that can impact clinical management of NSCLC patients care. METHODS: This study included 30 patients with EGFR-mutated NSCLC. Blood samples were collected at...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell-Free Nucleic Acids

Share to DNA, Neoplasm

Share to ErbB Receptors

Share to Liquid Biopsy

Share to Lung Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 34003366
DOI: 10.1007/s00432-021-03658-8
PMCID: PMC8236477

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EGFR mutation analysis on circulating free DNA in NSCLC: a single-center experience.PMID 34003366Read ↗

Clinical Utility of Liquid Biopsy (Cell-free DNA) Based EGFR Mutation Detection Post treatment Initiation as a Disease Monitoring Tool in Patients With Advanced EGFR-mutant NSCLC.Semantic proximity Read ↗

Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis.Semantic proximity Read ↗

Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value.Semantic proximity Read ↗

Associations between tumor mutations in cfDNA and survival in non-small cell lung cancer.Semantic proximity Read ↗

Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy.Semantic proximity Read ↗

Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial.Semantic proximity Read ↗

Role of Circulating Tumor DNA Profiling in Patients with Non-Small Cell Lung Cancer Treated with EGFR Inhibitor.Semantic proximity Read ↗

Plasma-based longitudinal mutation monitoring as a potential predictor of disease progression in subjects with adenocarcinoma in advanced non-small cell lung cancer.Semantic proximity Read ↗

Revolutionizing Non-Small Cell Lung Cancer Diagnosis: Ultra-High-Sensitive ctDNA Analysis for Detecting Hotspot Mutations with Long-term Stored Plasma.Semantic proximity Read ↗

Plasma Cell-Free DNA Genotyping: From an Emerging Concept to a Standard-of-Care Tool in Metastatic Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Liquid Biopsy for Disease Monitoring in Non-Small Cell Lung Cancer: The Link between Biology and the Clinic.Semantic proximity Read ↗

Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.